Inactivated Vaccines Market Report 2026

Inactivated Vaccines Market Overview

• Inactivated Vaccines market size has reached to $6.37 billion in 2025 • Expected to grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 5.1% • Growth Driver: Rising Prevalence Of Infectious Diseases Boost Inactivated Vaccines Market In Combating Diseases • Market Trend: Innovative Advancements In Inactivated Vaccines By Leading Companies For Disease Prevention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the inactivated vaccines market include: • Viral Vaccine (Segmentation By Type) → Expected gain of $2.38 Billion • Bacterial Vaccine (Segmentation By Type) → Expected gain of $0.89 Billion

What Is Covered Under Inactivated Vaccines Market?

Inactivated vaccines, also known as killed vaccines, are a type of vaccine that contains viruses or bacteria that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are designed to stimulate an immune response without causing disease in the vaccinated individual. The main types of inactivated vaccines are viral and bacterial vaccines. A viral vaccine is a biological preparation containing weakened or inactivated virus components to stimulate the immune system and provide immunity against the targeted viral infection. These are inactivated by solvent detergent, radiation, pH concentration, heat inactivation and others and are distributed by hospital pharmacies, retail pharmacies and others.

What Is The Inactivated Vaccines Market Growth Forecast?

The inactivated vaccines market size is expected to see strong growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing geriatric population, growth in emerging markets healthcare access, technological advancements in vaccine delivery systems, rise in global immunization initiatives, adoption of multi-dose and combination vaccines. Major trends in the forecast period include advancements in vaccine formulation, expansion of cold chain logistics, increasing demand for pediatric vaccines, growth in government immunization programs, development of combination vaccines.

What Is The Driver Of The Inactivated Vaccines Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the inactivated vaccine market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that can spread from person to person, resulting in a wide range of symptoms and health complications. Tuberculosis is one type of infectious disease. Inactivated vaccines use non-living pathogens to stimulate an immune response, effectively preventing diseases such as polio, hepatitis A and influenza. For instance, in November 2023, according to an article published by Centers for Disease Control and Prevention, a US-based national public health agency, the number of tuberculosis patients in the USA has increased from 8,320 in 2022 to 9,615 in 2023 indicating an increase of 1,295 cases. Therefore, the increasing prevalence of infectious diseases is driving the growth of the inactivated vaccine industry.

How Will The Drivers Impact Growth In The Global Inactivated Vaccines Market?

• Rising Government Immunization Programs and Pandemic Preparedness Initiatives (Medium) – During the forecast period, the Rising government immunization programs and pandemic preparedness initiatives is expected to become a key growth driver for the inactivated vaccines market by 2030. Governments worldwide are expanding national immunization programs and strengthening pandemic preparedness strategies to protect populations from infectious diseases. Inactivated vaccines are widely accepted in public vaccination campaigns because of their established safety profile and suitability for diverse population groups, including children and older adults. Increased public healthcare spending, vaccine stockpiling efforts, and international immunization initiatives are driving demand. The focus on improving vaccine coverage in emerging economies is further supporting market growth. • Growing Burden of Infectious Diseases (Medium) – During the forecast period, the growing burden of infectious diseases is expected to emerge as a major factor driving the expansion of the inactivated vaccines market by 2030. The increasing prevalence of infectious diseases such as influenza, hepatitis, polio, rabies, and Japanese encephalitis is boosting demand for preventive vaccination. Inactivated vaccines provide effective protection against many of these diseases while minimizing the risk of vaccine-derived infections. Rapid urbanization, international travel, and population growth have heightened disease transmission risks, encouraging broader vaccine adoption. Healthcare authorities are therefore investing heavily in vaccination programs to reduce disease-related morbidity and mortality. • Expansion of Vaccine Manufacturing Capacity and Technological Advancements (Low) – During the forecast period, the expansion of vaccine manufacturing capacity and technological advancements is expected to act as a key growth catalyst for the inactivated vaccines market by 2030. Pharmaceutical companies and vaccine manufacturers are investing significantly in expanding production facilities and improving vaccine manufacturing technologies. Advances in cell-culture techniques, purification processes, and adjuvant technologies have enhanced the efficacy and scalability of inactivated vaccines. These improvements enable manufacturers to meet growing global demand while maintaining high safety standards. Increased production capacity also strengthens supply chain resilience and supports faster vaccine distribution.

How Will The Restraints Impact Growth In The Global Inactivated Vaccines Market?

• Increasing Awareness of Preventive Healthcare (Medium) – During the forecast period, the growing public awareness regarding disease prevention and the benefits of vaccination is contributing to higher vaccine uptake globally. Educational campaigns by governments, healthcare organizations, and international agencies have improved understanding of vaccine effectiveness and safety. Consumers are increasingly prioritizing preventive healthcare measures to avoid costly medical treatments and disease complications. This trend is particularly evident in developing countries where vaccination coverage continues to expand, creating favorable conditions for market growth. • High Manufacturing and Quality Control Costs (Medium) – During the forecast period, the production of inactivated vaccines requires sophisticated manufacturing facilities, stringent biosafety measures, and extensive quality assurance processes. Pathogens must be cultivated and subsequently inactivated without compromising their immunogenic properties, making production complex and expensive. Regulatory requirements for safety testing and validation further increase operational costs. These factors can limit profitability and create barriers for new market entrants, particularly in low-income regions. • Requirement for Booster Doses and Lower Immunogenicity (Low) – During the forecast period, the compared with some live attenuated vaccines, inactivated vaccines often generate a weaker immune response and may require multiple doses or periodic booster shots to maintain protection. This can increase vaccination costs and reduce patient compliance, particularly in resource-constrained settings. Healthcare providers must invest additional resources in follow-up immunization programs. The need for repeated administration can therefore restrain widespread adoption in certain markets.

Key Players In The Global Inactivated Vaccines Market

Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

Global Inactivated Vaccines Market Trends and Insights

Major companies operating in the inactivated vaccines market are focusing on expanding product launches and securing regulatory approvals to strengthen their global vaccine portfolios and meet rising immunization needs. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK for use across all age groups in both pre-exposure and post-exposure situations. This launch highlights the company’s ongoing efforts to expand its range of inactivated vaccines and strengthen its global immunization offerings. The move also reflects increasing investments and rising regulatory momentum surrounding inactivated vaccine development and approvals. As more companies advance similar products and broaden their portfolios, these strategic initiatives are collectively driving significant growth in the inactivated vaccines market, supporting wider protection against infectious diseases.

What Are Latest Mergers And Acquisitions In The Inactivated Vaccines Market?

In October 2024, Mankind Pharma Limited, an India-based pharmaceutical company, acquired Bharat Serums & Vaccines Limited (BSV) for an undisclosed amount. With this acquisition, Mankind Pharma aimed to expand into high entry barrier biologics and vaccine manufacturing including capabilities in traditional inactivated vaccines thereby diversifying and upgrading its product portfolio. Bharat Serums & Vaccines is an India-based biopharmaceutical company that develops, manufactures, and markets recombinant biologics, complex injectables, and vaccines, including those using inactivated virus technology.

What Defines the Inactivated Vaccines Market?

The inactivated vaccines market consists of sales of whole-cell inactivated vaccines, subunit or protein subunit vaccines, conjugate vaccines and toxoid vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inactivated Vaccines Market Report 2026?

The inactivated vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.